Core Insights - The 2025 Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition showcased innovative projects, with a focus on technology and future industries [2] - The competition highlighted the collaboration between Hong Kong and mainland China in fostering biotech innovations, particularly in the context of the ICVAX HIV therapeutic vaccine project [4][8] Company Highlights - The ICVAX project, developed by MedK Bio, is based on patented technology from the University of Hong Kong, enhancing immune response against HIV [4][8] - MedK Bio secured a total of 85 million yuan in investment intentions from four institutions during the competition, with the highest single offer reaching 60 million yuan [7][13] - The project has achieved a 100% follow-up rate in its clinical trials, with safety and immunogenicity data exceeding expectations [4][5] Industry Collaboration - The project exemplifies the synergy between Hong Kong's research capabilities and mainland China's clinical resources, with Shenzhen Third People's Hospital serving as the primary clinical trial site [8][9] - MedK Bio's development path illustrates the integration of resources across the Greater Bay Area, enhancing the region's biotech innovation landscape [14] Future Prospects - MedK Bio plans to advance to Phase II clinical trials for ICVAX and expand its portfolio to include treatments for other infectious diseases and cancers, aiming for commercialization by 2028 [13][14] - The company is also collaborating with the National Manufacturing Innovation Center based in Shenzhen to establish a new laboratory [13]